交易中 08-04 11:10:39 美东时间
+1.055
+9.32%
Altisource Portfolio (NASDAQ:ASPS) reported quarterly earnings of $0.19 per share. This is a 111.31 percent increase over losses of $(1.68) per share from the same period last year. The company reported $40.787 million
07-24 19:10
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is likely to repo...
07-24 16:32
Altisource Portfolio Solutions S.A. (NASDAQ: ASPS) will report second-quarter 2025 earnings on July 24, 2025. A press release and presentation will be available on their Investor Relations website. The company will host a conference call at 8:30 a.m. EDT, with a live audio webcast accessible via the website. Participants should register and download necessary software in advance. A replay will be available approximately two hours after the call a...
07-21 16:45
Altisource Portfolio Solutions S.A. announced the impact of its 1-for-8 reverse stock split on its publicly traded warrants. The reverse stock split became effective on May 28, 2025. As a result, the Warrant Exercise Rate decreased from 1.625 to 0.20313, while the Implied Per Share Exercise Price increased from $1.20 to $9.5998. This means warrant holders will now receive fewer shares upon exercise. The warrants, split into "ASPSZ" and "ASPSW," m...
06-03 20:11
Altisource Portfolio Solutions S.A. ("Altisource" or the "Company") (NASDAQ:ASPS), a leading provider and marketplace for the real estate and mortgage industries, today announced that it will effect a consolidation of
05-23 19:44
一年一度的科技盛宴——台北国际电脑展(COMPUTEX)已于5月20日正式拉开帷幕,作为在主板硬件品牌深耕多年的企业MSI微星科技,在本次电脑展发布了众多创新成...
05-20 10:48
Shareholders Must Hold Shares in Multiples of Eight by Market Close on May 27, 2025 to Avoid Fractional Share Cash-OutLUXEMBOURG, May 13, 2025 (GLOBE NEWSWIRE) -- Altisource Portfolio Solutions S.A. ("Altisource" or the
05-14 00:20
Companies Reporting Before The Bell • Itron (NASDAQ:ITRI) is projected to repor...
05-01 16:32
The latest announcement is out from Altisource Portfolio Solutions SA ( ($ASPS)...
04-02 21:58
3月19日,贝达药业口服小分子PD-L1抑制剂BPI-371153研究进入Ib期扩大入组阶段并完成首例受试者入组,目标适应症为非小细胞肺癌和腺泡状软组织肉瘤。...
03-19 19:01